Andrew Campbell, Ana Silva-Pinto, Obiageli Nnodu, Deepa Manwani, Deborah Keefe, Jimmy Watson, Evgeniya Reshetnyak, Velusamy Muthusamy, Partha Banerjee, Olufolake Egbujo (Adisa), Michele Nassin, Yvonne Dei-Adomakoh. "A phase III, multicenter, randomized, placebo controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult sickle cell disease patients with frequent vaso-occlusive crises: The sparkle study." Blood (2025). https://doi.org/10.1182/blood-2025-1198